XSTOBIOVIT
Market cap860kUSD
Jan 02, Last price
0.25SEK
Name
Hemcheck Sweden AB
Chart & Performance
P/E
—
P/S
7.20
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.74%
Rev. gr., 5y
165.52%
Revenues
1m
+17.78%
Net income
-15m
L+6.55%
CFO
-8m
L-3.43%
Profile
Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden. The company develops and commercializes Helge, which detects hemolysis in blood samples at the point of care. It serves emergency departments in the European Union and the United States. The company was founded in 2010 and is based in Karlstad, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | |||||||||
Revenues | 1,320 17.78% | 1,121 265.24% | |||||||
Cost of revenue | 4,218 | 7,672 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,898) | (6,552) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (30) | 848 | |||||||
Tax Rate | |||||||||
NOPAT | (2,868) | (6,552) | |||||||
Net income | (14,870) 6.55% | (13,955) 18.96% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 6,288 | 13,965 | |||||||
BB yield | -211.82% | -37.96% | |||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 89 | ||||||||
Net debt | (3,186) | (8,789) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (7,906) | (8,187) | |||||||
CAPEX | (3,985) | (3,361) | |||||||
Cash from investing activities | (3,985) | (3,361) | |||||||
Cash from financing activities | 6,288 | 13,965 | |||||||
FCF | (2,513) | (6,436) | |||||||
| Balance | |||||||||
Cash | 3,186 | 8,789 | |||||||
Long term investments | |||||||||
Excess cash | 3,120 | 8,733 | |||||||
Stockholders' equity | (79,069) | (68,247) | |||||||
Invested Capital | 103,993 | 101,781 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 15,708 | 19,109 | |||||||
Price | 0.19 -90.18% | 1.93 -59.13% | |||||||
Market cap | 2,969 -91.93% | 36,785 -59.63% | |||||||
EV | (217) | 27,996 | |||||||
EBITDA | 4,257 | (99) | |||||||
EV/EBITDA | |||||||||
Interest | 165 | 848 | |||||||
Interest/NOPBT | |||||||||